Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR) [View news story]
Speculators are net long $51B in major equity index futures contracts, according to the latest CFTC data. By comparison - ahead of a major rally - they were net short $58B worth one year ago. (h/t Jason Goepfert) [View news story]
Somebody give me one good reason why this market should move-pls.
Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR) [View news story]
The S&P 500 Returns Imply Real GDP Growth 4% In Q3 [View article]
Speculators are net long $51B in major equity index futures contracts, according to the latest CFTC data. By comparison - ahead of a major rally - they were net short $58B worth one year ago. (h/t Jason Goepfert) [View news story]
Natural Gas: A Relatively Safe, Long-Term Investment With Significant Upside [View article]
Sturm Ruger & Company (RGR): Q2 EPS of $0.91 beats by $0.11. Revenue of $119.6M (+50.3% Y/Y) beats by $12M. (PR) [View news story]